Half of GLP-1 Patients Stop Taking Their Medication. Here Is What That Means for Lexaria.

GLP-1 drugs have become one of the biggest success stories in pharmaceuticals. In 2025, the top seven branded products generated more than $73 billion in worldwide revenue. Clinical results have been strong and demand continues expanding into new areas including cardiovascular disease, kidney disease, and sleep apnea.

And yet roughly half of patients stop taking them within a year.

That is not a small problem. It is a central commercial challenge facing the entire GLP-1 industry, and one that Lexaria Bioscience (Nasdaq: LEXX) has been quietly building toward solving.

Why Patients Stop

A large six-year study of over 125,000 patients found discontinuation rates of 46.5% for those with diabetes and 64.8% for those using the drugs primarily for weight loss. Gastrointestinal side effects are a leading driver. Nausea, vomiting, diarrhea, and constipation are reported consistently across the GLP-1 drug class regardless of whether the drug is injected or taken orally.

In trials of injected semaglutide, a majority of patients reported GI side effects. In trials of oral semaglutide, reported rates were higher.

In a separate survey of 2,173 patients who had discontinued GLP-1 treatment, most cited GI discomfort and aversion to injections as their primary reasons for stopping.

This is not a fringe patient experience. It is widely observed across the category.

What It Costs the Industry

With a market generating over $73 billion annually and a significant portion of patients discontinuing within a year, the impact on long-term utilization is meaningful. Every patient who quits is a patient who needs to be replaced to sustain growth. As GLP-1 drugs expand into new indications, the discontinuation problem scales with the market.

Novo Nordisk and Eli Lilly are both investing aggressively in oral delivery, correctly identifying it as the format patients prefer. But oral delivery brings its own tolerability challenges. More drug is needed to achieve the same effect as an injection, and higher drug concentrations tend to contribute to tolerability issues.

Addressing tolerability is not a secondary concern. It is a prerequisite for sustainable market growth.

Where Lexaria Fits

Lexaria is not developing GLP-1 drugs. The company is focused on the delivery layer and specifically on whether that delivery can be improved to reduce the side effects that are driving patients away.

DehydraTECH is Lexaria’s patented oral drug delivery platform. Over the past two years, the company has completed five human clinical studies across semaglutide, tirzepatide, and liraglutide. Across those studies, DehydraTECH formulations reported reduced adverse event profiles relative to study controls. In the largest, a registered Phase 1b trial with 126 participants, DehydraTECH-semaglutide showed reductions in total and gastrointestinal adverse events relative to the Rybelsus control arm.

The platform has also shown increased brain biodistribution of certain active ingredients relative to controls, a finding that is becoming increasingly relevant as researchers explore the role of brain neurochemistry in GLP-1 drug performance.

Building on the Data

Lexaria is not standing still. In 2026 the company initiated a new human study comparing enhanced DehydraTECH-semaglutide formulations against commercial Wegovy tablets, with results expected later this year. A new animal study is also underway to explore further formulation improvements and strengthen the IP portfolio. The company currently holds 65 patents worldwide with additional patents pending.

The Licensing Model

Lexaria operates through licensing. It generates clinical data and patents, then seeks to partner with pharmaceutical companies that may want access to the technology. The commercial rationale is straightforward. If a delivery platform can reduce side effects while maintaining drug performance, it may have value to companies operating in this space.

Precedent for delivery technology transactions is well established. Novo Nordisk paid $1.8 billion for SNAC, the delivery technology behind Rybelsus and Wegovy oral tablets. Pfizer acquired Metsera for $7 billion. Merck licensed Cyprumed’s oral peptide delivery technology for up to $493 million in milestones.

Lexaria is a small company. The stock reflects that. But the problem it is addressing is significant, the clinical data has been reported, and the commercial pathway aligns with existing industry activity.

The dropout problem is not going away. If anything it is getting larger as the market expands. That is the opportunity Lexaria is building toward.